Beckmann et al v. Lyman - Page 8




              Interference No. 105,099                                                           Paper 25                 
              Hannum v. Immunex Corp.                                                               Page 8                
                     Immunex: NFKVKFRELTDHLLKDYPVTVAVNLQDEKHCKAL......     74                                             
                     MoT118: NFKVKFRELTDHLLKDYPVTVAVNLQDEKHCKAL......     74                                              
                     MoT110: NFKVKFRELTDHLLKDYPVTVAVNLQDEKHCKAL......     74                                              
                     MB8:          NFKVKFRELTDHLLKDYPVTVAVNLQDEKHCKALDRVSLL     80                                        
                     Immunex: .......................WSLFLAQRWIEQLKTVA     91                                             
                     MoT118: .......................WSLFLAQRWIEQLKTVA     91                                              
                     MoT110: .......................WSLFLAQRWIEQLKTVA     91                                              
                     MB8:          CRLGLTLNSLQSSCLSVLSAGITWSLFLAQRWIEQLKTVA    120                                        
                     Immunex: GSKMQTLLEDVNTEIHFVTSCTFQPLPECLRFVQTNISHL    131                                             
                     MoT118:       GSKMQTLLEDVNTEIHFVTSCTFQPLPECLRFVQTNISHL    131                                        
                     MoT110:       GSKMQTLLEDVNTEIHFVTSCTFQPLPECLRFVQTNISHL    131                                        
                     MB8:          GSKMQTLLEDVNTEIHFVTSCTFQPLPECLRFVQTNISHL    160                                        
                     Immunex: LKDTCTQLLALKPCIFKACQNFSRCLEVQCQPDSSTLLPP    171                                             
                     MoT118:       LKDTCTQLLALKPCIFKACQNFSRCLEVQCQPGNGGPRAQ    171                                        
                     MoT110:       LKDTCTQLLALKPCIFKACQNFSRCLEVQCQPDSSTLLPP    171                                        
                     MB8:          LKDTCTQLLALKPCIFKACQNFSRCLEVQCQPDSSTLLPP    200                                        
                     Immunex: RSPIALEATELPEPRPRQLLLLLLLL.PLTLVLLAAAWGL    210                                             
                     MoT118:       HHGATRLTATALLTVCPGLLLPLVGT.SHMFFLPYFLSFL    210                                        
                     MoT110:       RSPIALEATELPEPRPRQLLLLLLLLLPLTLVLLAAAWGL    211                                        
                     MB8:          RSPIALEATELPEPRPRQLLLLLLLLLPLTLVLLAAAWGL    240                                        
                     Immunex: RWQRARRRGELHPGVPLPSHP                       231                                             
                     MoT118: SSFLKMYLYV...........                       220                                              
                     MoT110:       RWQRARRRGELHPGVPLPSHP                       232                                        
                     MB8:          RWQRARRRGELHPGVPLPSHP                       261                                        
       [28] The examiner argues that a consensus sequence between the three Immunex isoforms                              
              would yield Immunex SEQ ID NO:2.  If we ignore MB8 as simply a variant of MoT110, it                        
              is not clear how one skilled in the art would choose a consensus sequence between the                       
              two isoforms.  Alternatively, if MB8 is considered, the simplest consensus sequence                         
              (majority rule at each differing position, gaps permitted) would yield the MoT110                           
              sequence, which differs from Immunex SEQ ID NO:2 by the addition of a leucine                               
              residue at position 198.                                                                                    







Page:  Previous  1  2  3  4  5  6  7  8  9  10  11  12  13  Next 

Last modified: November 3, 2007